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A number of observations have radi-
cally expanded our knowledge regarding
the signaling pathways that regulate the
tumor suppressor PTEN. These findings
are derived from the molecular charac-
terization of cancer-associated dominant-
negative PTEN mutants, as well as the iden-
tification of alternative forms and intracel-
lular localizations of PTEN.
The lipid and protein phosphatase
PTEN (Phosphatase and tensin homolog
located on chromosome 10) is one of the
most common tumor suppressors that is
lost or mutated in several human can-
cers. Different mechanisms contribute to
PTEN loss of function, which include
post-translational modifications, interac-
tion with other proteins, missense and
truncation mutations, as well as gene dele-
tions. The role of PTEN as an oncosuppres-
sor has mainly been characterized through
the study of different PTEN -null tumor
cell lines or transgenic mice engineered to
carry one wild-type (WT) copy and one
null allele of PTEN (PTEN+/−). How-
ever, a paper published in 1998 by the
group of Eng and co-workers reported that
PTEN loss-of-function mutations might
not contribute to tumorigenesis to the
same extent as the genetic loss of PTEN.
This study was conducted on patients
affected by Cowden disease, a PTEN
hamartoma tumor syndrome, and revealed
that patients with missense PTEN muta-
tions in the phosphatase domain devel-
oped higher numbers of lesions com-
pared to patients with truncating muta-
tions (1). The mechanistic and molecular
role of PTEN mutations in cancer has been
recently defined in a paper published inCell
(2). Papa et al. showed that different PTEN
mutants, previously identified in tumors
(i.e., PTEN C124S, PTEN G129E, and
PTEN R130G), form heterodimeric struc-
tures with the WT enzyme, thereby inhibit-
ing PTEN activity in a dominant-negative
manner and leading to aberrant Akt acti-
vation (2). Moreover, it has been observed
that dephosphorylation of the PTEN tail
not only promotes an open conformation
of the enzyme but also favors the forma-
tion of dimers or oligomers (2). The het-
erozygous expression of cancer-associated
PTEN mutations allows the generation of
catalytically inactive heterodimers. Conse-
quently, increased PIP3 levels induce Akt
hyperactivation and augment tumor pro-
gression. Thus, a neoplasm characterized
by PTEN mutations is more unfavorable
than a PTEN-null cancer context. Interest-
ingly, this now reveals that the malignant
activity of mutant PTENs is analogous to
that of mutant p53: p53, a tumor sup-
pressor also frequently mutated in cancers,
normally functions in a tetrameric confor-
mation; moreover, p53 mutants can simi-
larly act as dominant-negative inhibitors of
residual WT protein (3).
The ability of mutant PTEN to het-
erodimerize and inhibit the WT enzymatic
activity is one of the recent findings that
have radically expanded our knowledge
on PTEN activity and functions. Firstly,
the identification of an alternative vari-
ant of PTEN, named PTEN-Long, contain-
ing an extra 173 aminoacidic domain at
its N-terminus, followed by the canonical
PTEN sequence (4). The resulting 576-
aminoacids protein is less abundant than
the short isoform; it has been founded to
be mutated in tumor samples and can be
secreted to enter other cells (4, 5).
Furthermore, it has been shown as
PTENα, a 70-kDa PTEN variant that most
likely corresponds to PTEN-Long (5), con-
trols mitochondrial metabolism and the
energy status of the cell (6). PTENα can
interact with canonical PTEN, forming
heterodimers that regulate mitochondr-
ial bioenergetics (6). Interestingly, trans-
genic mouse lines with PTEN expression
displayed increased mitochondrial oxida-
tive phosphorylation and ATP production
(7). Unlike canonical PTEN, which plays
a well-defined role in signaling at the
plasma membrane and nucleus, PTENα
localizes mainly to the cytosol and mito-
chondria (6). In line with this, alterna-
tive subcellular localizations of PTEN, such
as to the nucleoli (8) and mitochondria-
associated endoplasmic reticulum mem-
branes (MAM) (9), have been recently
described. Our group demonstrated that
PTEN interacts with the inositol-1,4,5-
trisphosphate receptor (IP3R) at endo-
plasmic reticulum (ER) to counteract
Akt activity, consequently favoring cal-
cium (Ca2+) transfer into the mitochon-
dria and the initiation of apoptosis (9,
10). Accordingly, we and other labs pro-
posed that Akt kinase might potentiate its
anti-apoptotic activity through IP3R phos-
phorylation and the reduction of Ca2+
release from the ER (11–14). Thus, PTEN
acts at multiple subcellular levels, regulat-
ing PI3K signaling through its phosphatase
activity.
Although the ER-targeted C124S and
G129E PTEN chimeras still maintain their
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ability to suppress Akt activation (9),
there is currently no evidence that cancer-
associated PTEN mutants operate at spe-
cific subcellular compartments. Neverthe-
less, upon starvation/serum stimulation,
C124S and G129E mutants translocate
more rapidly to the plasma membrane than
the WT form (2).
The very recent characterization of a
bioluminescence resonance energy transfer
(BRET)-based biosensor, which is capable
of detecting signal-dependent PTEN con-
formational changes in live cells (15), may
represent a valuable tool for elucidating
PTEN activity and functions.
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